More than 50 million people worldwide suffer from one of the most common neurological diseases: epilepsy.
The main treatment for epilepsy is pharmacotherapy with anti-seizure drugs.
Drug treatment, however, has two major disadvantages:
- Anti-seizure drugs can cause severe side effects that lower quality of life
- About one-third of patients are drug-resistant, do not respond to treatment, and continue to have uncontrolled seizures.
Seizures cause neurovascular inflammation and barrier leakage resulting in barrier dysfunction. Barrier dysfunction, in turn, triggers new seizures, leading to a pernicious cycle that contributes to drug resistance and drives epilepsy pathology.
We are currently evaluating the therapeutic benefit of a novel, patented treatment that targets the underlying mechanism causing barrier dysfunction in epilepsy. Our approach is designed to resolve inflammation and repair barrier dysfunction to overcome drug resistance and reduce seizures to help patients with epilepsy.